Reversal of left ventricular remodeling: Role of the endothelin pathway

Journal of Cardiac Failure

Volumn 8, Issue 6 SUPPL., 2002, Pages

  Teerlink, John R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Endothelin; Endothelin antagonists; Heart failure; Ventricular remodeling; Ventricular volumes

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; DARUSENTAN; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; NEUROHORMONE;

CONFERENCE PAPER; DEVELOPMENT; HEART LEFT VENTRICLE; HEART VENTRICLE REMODELING; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 0036947236     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1054/jcaf.2002.129288     Document Type: Conference Paper

References (39)

1. Masaki T: The discovery of endothelins. Cardiovasc Res 1998;39:530-533
2. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415
3. Miyauchi T, Masaki T: Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol 1999;61:391-415
4. Cernacek P, Stewart DJ: Immunoreactive endothelin in human plasma: Marked elevations in patients in cardiogenic shock. Biochem Biophys Res Commun 1989;161:562-567
5. Margulies KB, Hildebrand FL Jr, Lerman A, Perrella MA, Burnett Jr JC: Increased endothelin in experimental heart failure. Circulation 1990;82:2226-2230
6. Teerlink JR, Löffler BM, Hess P, Maire JP, Clozel M, Clozel JP: Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). Circulation 1994;90:2510-2518
7. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R: Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992;85:504-509
8. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K: Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994;89:1573-1579
9. Pacher R, Stanek B, Hülsmann M, Koller-Strametz J, Berger R, Schuller M, Hartter E, Ogris E, Frey B, Heinz G, Maurer G: Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996;27:633-641
10. Kobayashi T, Miyauchi T, Sakai S, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y: Expression of endothelin-1, ETA and ETB receptors, and ECE and distribution of endothelin-1 in failing rat heart. Am J Physiol Heart Circ Physiol 1999;276:H1197-1206
11. Thorin E, Lucas M, Cernacek P, Dupuis J: Role of ET(A) receptors in the regulation of vascular reactivity in rats with congestive heart failure. Am J Physiol Heart Circ Physiol. 2000;279:H844-851
12. Loennechen JP, Støylen A, Beisvag V, Wisløff U, Ellingsen O: Regional expression of endothelin-1, ANP, IGF-1, and LV wall stress in the infarcted rat heart. Am J Physiol Heart Circ Physiol 2001;280:H2902-2910
13. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Horie H, Sugimoto Y, Kinoshita M: Transcardiac extraction of circulating endothelin-1 across the failing heart. Am J Cardiol 2000;86:524-528
14. Teerlink JR, Carteaux JP, Sprecher U, Löffler BM, Clozel M, Clozel JP: Role of endogenous endothelin in normal hemodynamic status of anesthetized dogs. Am J Physiol Heart Circ Physiol 1995;268:H432-440
15. Love MP, Haynes WG, Gray GA, Webb DJ, McMurray JJ: Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation 1996;94:2131-2137
16. Piacentini L, Gray M, Honbo NY, Chentoufi J, Bergman M, Karliner JS: Endothelin-1 stimulates cardiac fibroblast proliferation through activation of protein kinase C. J Mol Cell Cardiol 2000;32:565-576
17. Belloni AS, Rossi GP, Andreis PG, Neri G, Albertin G, Pessina AC, Nussdorfer GG: Endothelin adrenocortical secretagogue effect is mediated by the B receptor in rats. Hypertension 1996;27:1153-1159
18. Yoshida K, Yasujima M, Kohzuki M, Kanazawa M, Yoshinaga K, Abe K: Endothelin-1 augments pressor response to angiotensin II infusion in rats. Hypertension 1992;20:292-297
19. Kaddoura S, Firth JD, Boheler KR, Sugden PH, Poole-Wilson PA: Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist. Circulation 1996;93:2068-2079
20. Riggleman A, Harvey J, Baylis C: Endothelin mediates some of the renal actions of acutely administered angiotensin II. Hypertension 2001;38:105-109
21. Ramires FJA, Sun Y, Mady C, Ramires JAF, Weber KT: Effect of endothelin on myocardial fibrosis in response to chronic administration of angiotensin II or aldosterone. Circulation 1999;100:1474 (abstract)
22. Grover GJ, Dzwonczyk S, Parham CS: The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc Res 1993;27:1613-1618
23. Burke SE, Nelson RA: Endothelin-receptor antagonist FR 139317 reduces infarct size in a rabbit model when given before, but not after, coronary artery occlusion. J Cardiovasc Pharmacol 1997;29:87-92
24. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y: Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996;384:353-355
25. Mulder P, Richard V, Bouchart F, Derumeaux G, Münter K, Thuillez C: Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure. Cardiovasc Res 1998;39:600-608
26. Nguyen QT, Cernacek P, Calderoni A, Stewart DJ, Picard P, Sirois P, White M, Rouleau JL: Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat. Circulation 1998;98:2323-2330
27. Hu K, Gaudron P, Schmidt TJ, Hoffman KD, Ertl G: Aggravation of left ventricular remodeling by a novel specific endothelin ET(A) antagonist EMD94246 in rats with experimental myocardial infarction. J Cardiovasc Pharmacol 1998;32:505-508
28. Podesser BK, Siwik DA, Eberli FR, Sam F, Ngoy S, Lambert J, Ngo K, Apstein CS, Colucci WS: ET(A)-receptor blockade prevents matrix metalloproteinase activation late postmyocardial infarction in the rat. Am J Physiol Heart Circ Physiol 2001;280:H984-991
29. Spinale FG, Walker JD, Mukherjee R, Iannini JP, Keever AT, Gallagher KP: Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits. Beneficial effects on left ventricular and myocyte function. Circulation 1997;95:1918-1929
30. Moe GW, Albernaz A, Naik GO, Kirchengast M, Stewart DJ: Beneficial effects of long-term selective endothelin type A receptor blockade in canine experimental heart failure. Cardiovasc Res 1998;39:571-579
31. Clozel M, Breu V, Gray GA, Kalina B, Löffler BM, Burri K, Cassal JM, Hirth G, Müller M, Neidhart W, et al: Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994;270:228-235
32. Mulder P, Richard V, Derumeaux G, Hogie M, Henry JP, Lallemand F, Compagnon P, Macé B, Comoy E, Letac B, Thuillez C: Role of endogenous endothelin in chronic heart failure: Effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 1997;96:1976-1982
33. Fraccarollo D, Hu K, Galuppo P, Gaudron P, Ertl G: Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: Possible involvement of myocardial endothelin system in ventricular remodeling. Circulation 1997;96:3963-3973
34. Oie E, Bjonerheim R, Grogaard HK, Kongshaug H, Smiseth OA, Attramadal H: ET-receptor antagonism, myocardial gene expression, and ventricular remodeling during CHF in rats. Am J Physiol 1998;275:H868-877
35. Schafhalter-Zoppoth I, Teerlink JR. Endothelin antagonism with bosentan improves myocardial mechanics and ventricular remodeling in rats with chronic heart failure. J Am Coll Cardiol 2002;39:171A (abstract)
36. Schafhalter-Zoppoth I, Gray MO, Teerlink JR: Endothelin antagonism with bosentan, a dual receptor blocker, normalizes dysregulated transforming growth factor beta signaling pathways in rats with chronic heart failure. J Am Coll Cardiol 2002;39:168A (abstract)
37. Iwanaga Y, Kihara Y, Inagaki K, Onozawa Y, Yoneda T, Kataoka Y, Sasayama S: Differential effects of angiotensin II versus endothelin-1 inhibitions in hypertrophic left ventricular myocardium during transition to heart failure. Circulation 2001;104:606-612
38. Mishima T, Tanimura M, Suzuki G, Todor A, Sharov VG, Goldstein S, Sabbah HN: Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure. J Am Coll Cardiol 2000;35:222-229
39. Mylona P, Cleland JG: Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team. Eur J Heart Fail 1999;1:197-200